Pharmacoeconomic review report Dapagliflozin (Forxiga)
Dapagliflozin (Forxiga) is an oral antihyperglycemic drug of the sodium‐glucose cotransporter 2 (SGLT2) inhibitor class. This CADTH Common Drug Review (CDR) focuses on dapagliflozin for the treatment of patients with type 2 diabetes mellitus (T2DM) to improve glycemic control when added on to metfor...
| Main Author: | |
|---|---|
| Corporate Author: | |
| Format: | eBook |
| Language: | Inglés |
| Published: |
Ottawa (ON) :
Canadian Agency for Drugs and Technologies in Health
2016.
|
| Subjects: | |
| See on Biblioteca Universitat Ramon Llull: | https://discovery.url.edu/permalink/34CSUC_URL/1im36ta/alma991009820270506719 |
| Summary: | Dapagliflozin (Forxiga) is an oral antihyperglycemic drug of the sodium‐glucose cotransporter 2 (SGLT2) inhibitor class. This CADTH Common Drug Review (CDR) focuses on dapagliflozin for the treatment of patients with type 2 diabetes mellitus (T2DM) to improve glycemic control when added on to metformin and a sulfonylurea for patients with inadequate glycemic control on combination therapy with metformin and a sulfonylurea and for whom insulin is not an option. |
|---|---|
| Physical Description: | 1 online resource |
